Contact Us
Drug Search Results
More Filters [+]

Vaniprevir

Alternative Names: vaniprevir, mk-7009, mk7009, mk 7009
Latest Update: 2024-06-21
Latest Update Note: News Article

Product Description

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vaniprevir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hepatitis C, Chronic|Hepatitis A

Phase 2: Hepatitis C|Hepatitis A|Hepatitis C, Chronic|Communicable Diseases

Phase 1: Hepatitis A|Hepatitis C|Hepatitis C, Chronic|Hepatic Insufficiency|Liver Failure

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MK-7009-048

P1

Completed

Hepatitis A|Hepatitis C, Chronic

2013-08-27

MK-7009-043

P3

Completed

Hepatitis C, Chronic|Hepatitis A

2013-07-31

2009-013053-15

P2

Completed

Hepatitis C

2013-05-29

MK-7009-028

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2013-05-29

Recent News Events

Date

Type

Title

06/21/2024

News Article

 Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

08/17/2021

PubMed

 Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.

05/18/2021

PubMed

 Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.

06/01/2020

PubMed

 Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection.

06/19/2019

News Article

 Schrödinger Bolsters Translational Science Expertise with Leadership Expansion

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions